StockMacro
Company, fund or insider

Help

Menu

TScan Therapeutics

$0.15 -86% in 6 monthsMarket cap $9.9M

TCRX on XNAS, Health Care, TScan Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Delisting notice filed as the stock fell 85% in a year and revenue dropped 38%.

  • BadLayoff notices for 96 workers, up from none the year before
  • BadNet loss of $115.1M over 12 months, with cash outflow of $111.7M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
142
Website
tscan.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 3 Mar 2027 (an estimate: a year ago it reported on 4 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $586K, net loss $33.1M.
Quarter to 31 Dec 2021: revenue $2.9M, net income -$14.2MQuarter to 31 Dec 2021: revenue $2.9M, net income -$14.2MQuarter to 31 Mar 2022: revenue $3.0M, net income -$16.2MQuarter to 31 Mar 2022: revenue $3.0M, net income -$16.2MQuarter to 30 Jun 2022: revenue $4.1M, net income -$15.1MQuarter to 30 Jun 2022: revenue $4.1M, net income -$15.1MQuarter to 30 Sep 2022: revenue $3.4M, net income -$16.2MQuarter to 30 Sep 2022: revenue $3.4M, net income -$16.2MQuarter to 31 Dec 2022: revenue $3.1M, net income -$18.7MQuarter to 31 Dec 2022: revenue $3.1M, net income -$18.7MQuarter to 31 Mar 2023: revenue $6.8M, net income -$22.6MQuarter to 31 Mar 2023: revenue $6.8M, net income -$22.6MQuarter to 30 Jun 2023: revenue $3.1M, net income -$24.0MQuarter to 30 Jun 2023: revenue $3.1M, net income -$24.0MQuarter to 30 Sep 2023: revenue $3.9M, net income -$23.0MQuarter to 30 Sep 2023: revenue $3.9M, net income -$23.0MQuarter to 31 Dec 2023: revenue $7.2M, net income -$19.6MQuarter to 31 Dec 2023: revenue $7.2M, net income -$19.6MQuarter to 31 Mar 2024: revenue $566K, net income -$30.1MQuarter to 31 Mar 2024: revenue $566K, net income -$30.1MQuarter to 30 Jun 2024: revenue $536K, net income -$31.7MQuarter to 30 Jun 2024: revenue $536K, net income -$31.7MQuarter to 30 Sep 2024: revenue $1.0M, net income -$29.9MQuarter to 30 Sep 2024: revenue $1.0M, net income -$29.9MQuarter to 31 Dec 2024: revenue $665K, net income -$35.8MQuarter to 31 Dec 2024: revenue $665K, net income -$35.8MQuarter to 31 Mar 2025: revenue $2.2M, net income -$34.1MQuarter to 31 Mar 2025: revenue $2.2M, net income -$34.1MQuarter to 30 Jun 2025: revenue $3.1M, net income -$37.0MQuarter to 30 Jun 2025: revenue $3.1M, net income -$37.0MQuarter to 30 Sep 2025: revenue $2.5M, net income -$35.7MQuarter to 30 Sep 2025: revenue $2.5M, net income -$35.7MQuarter to 31 Dec 2025: revenue $2.6M, net income -$23.0MQuarter to 31 Dec 2025: revenue $2.6M, net income -$23.0MQuarter to 31 Mar 2026: revenue $982K, net income -$28.7MQuarter to 31 Mar 2026: revenue $982K, net income -$28.7MQuarter to 30 Jun 2026: revenue $1.1M, net income -$30.4MQuarter to 30 Jun 2026: revenue $1.1M, net income -$30.4MQuarter to 30 Sep 2026: revenue $586K, net income -$33.1MQuarter to 30 Sep 2026: revenue $586K, net income -$33.1M
31 Dec 2021RevenueNet incomeNet losstallest bar $37.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$586K-$33.1M
30 Jun 2026$1.1M-$30.4M
31 Mar 2026$982K-$28.7M
31 Dec 2025$2.6M-$23.0M
30 Sep 2025$2.5M-$35.7M
30 Jun 2025$3.1M-$37.0M
31 Mar 2025$2.2M-$34.1M
31 Dec 2024$665K-$35.8M
30 Sep 2024$1.0M-$29.9M
30 Jun 2024$536K-$31.7M
31 Mar 2024$566K-$30.1M
31 Dec 2023$7.2M-$19.6M
30 Sep 2023$3.9M-$23.0M
30 Jun 2023$3.1M-$24.0M
31 Mar 2023$6.8M-$22.6M
31 Dec 2022$3.1M-$18.7M
30 Sep 2022$3.4M-$16.2M
30 Jun 2022$4.1M-$15.1M
31 Mar 2022$3.0M-$16.2M
31 Dec 2021$2.9M-$14.2M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $5.2M $8.4M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -38% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$115.1M -$142.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -126% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$111.7M -$135.9M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $73.0M $184.5M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $33.0M $32.4M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$40.1M (net cash) -$152.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.87 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. –
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 1.9 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.26 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
TScan TherapeuticsTCRX (this company) $9.9Mloss1.9-38%–
aTyr PharmaATYR $9.7Mloss–––
Jasper TherapeuticsJSPR $9.6Mloss–––
Dyadic InternationalDYAI $11.5Mloss3.7-7.6%-227%
BioCardiaBCDA $11.9Mloss–––
IN8bioINAB $8.2Mloss–––

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-97%

$41K vs $1.4M (quarter ended 30 Sep 2026)

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-12%

52 13F filers vs 59

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

–

No 13F holdings or share count.

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

–

2.0M shares sold short (30 Oct 2026); no share count in the company's filings in our data

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.7

2.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-11%

2.3M shares sold short in the report before, 2.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

39%

39% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 36%

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

96

the 12 months before: 0

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

6

6 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

6 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Layoff notice 96 workers

Price $0.15 on 20 Nov 2026, -85% over 12 months (12-month range $0.14 to $1.43)

  • Sharp change
  • 8-K and other filings
  • WARN layoff notice
Insider net buying (open market). Insiders bought a net $146K in the last 12 months (the 12 months before: $3.5M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 7 published in the last 12 months, -12% on the 12 months before.
Revenue per quarter. Revenue $586K in the latest quarter, -77% on a year earlier.
Capital spending per quarter. Capital spending $41K in the latest quarter, -97% on a year earlier.
Institutional holders (13F filers). 52 13F filers reported holding it in the latest 13F quarter, -29% on a year earlier.
Workers in WARN layoff notices. Workers in WARN layoff notices: 96 published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Oct 20268-K and other filingsDirector or officer change
30 Sep 20268-K and other filingsDirector or officer change
11 Sep 20268-K and other filingsDirector or officer change
3 Sep 2026WARN layoff noticeTScan Therapeutics Inc. (dba TScan), 96 workers, Waltham, MA, MA
3 Sep 2026Sharp changeWARN layoff notice: wARN layoff notice (1 event(s) in 30 days, workers total 96)
2 Sep 20268-K and other filingsRestructuring costs announced
2 Sep 20268-K and other filingsDirector or officer change
2 Sep 20268-K and other filingsDelisting notice or listing transfer
2 Sep 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Aug 20268-K and other filingsA major agreement ended
2 Apr 20268-K and other filingsDirector or officer change
2 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 Nov 20258-K and other filingsDirector or officer change
26 Nov 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Nov 20258-K and other filingsRestructuring costs announced
20 Aug 20258-K and other filingsDirector or officer change
20 Aug 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Jan 2025Sharp changeShort interest spike: short interest spike, 2.5M vs usual 560K (2024-12-31); 8.3x the same period a year earlier
31 Dec 2024Sharp changeShort interest spike: short interest spike, 2.3M vs usual 498K (2024-12-13); 6.6x the same period a year earlier
23 Dec 20248-K and other filingsA major agreement ended
17 Dec 2024Sharp changeShort interest spike: short interest spike, 2.3M vs usual 451K (2024-11-29); 6.2x the same period a year earlier
3 Dec 2024Sharp changeShort interest spike: short interest spike, 2.3M vs usual 418K (2024-11-15); 5.5x the same period a year earlier
19 Nov 2024Sharp changeShort interest spike: short interest spike, 2.2M vs usual 418K (2024-10-31); 4.6x the same period a year earlier
29 Oct 2024Sharp changeShort interest spike: short interest spike, 2.2M vs usual 418K (2024-10-15); 4.3x the same period a year earlier
15 Oct 2024Sharp changeShort interest spike: short interest spike, 2.1M vs usual 418K (2024-09-30); 3.6x the same period a year earlier
1 Oct 2024Sharp changeShort interest spike: short interest spike, 1.8M vs usual 407K (2024-09-13); 4.8x the same period a year earlier
17 Sep 2024Sharp changeShort interest spike: short interest spike, 1.4M vs usual 390K (2024-08-30); 4.1x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 1.3M vs usual 379K (2024-08-15); 3.6x the same period a year earlier
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 29 vs usual 5 (2024-06-30); 5.8x the same period a year earlier
13 Aug 2024Sharp changeShort interest spike: short interest spike, 1.2M vs usual 379K (2024-07-31); 3.0x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 1.0M vs usual 375K (2024-07-15); 2.8x the same period a year earlier
14 Jun 20248-K and other filingsDirector or officer change
14 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Jan 20248-K and other filingsDirector or officer change
7 Dec 20238-K and other filingsDirector or officer change
7 Dec 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 Jul 20238-K and other filingsDirector or officer change
29 Jun 20238-K and other filingsDirector or officer change
15 Jun 20238-K and other filingsDirector or officer change
31 May 20238-K and other filingsDirector or officer change
10 Apr 20238-K and other filingsDirector or officer change
31 Mar 20238-K and other filingsDirector or officer change
31 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
7 Jul 20228-K and other filingsDirector or officer change
3 Jun 20228-K and other filingsDirector or officer change
3 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Mar 2022: $51K published
Month from 1 May 2022: $2.6M published
Month from 1 Dec 2022: $9K published
Month from 1 Jun 2023: $36K published
Month from 1 Dec 2023: $168K published
Month from 1 Aug 2024: -$896K published
Month from 1 Sep 2024: $26K published
Month from 1 Nov 2024: $4K published
Month from 1 Dec 2024: $386K published
Month from 1 May 2025: $3.1M published
Month from 1 Dec 2025: $146K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2023: 2 published
Quarter from 1 Jul 2024: 3 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jan 2025: 4 published
Quarter from 1 Jul 2025: 3 published
Quarter from 1 Oct 2025: 1 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 4 published
Quarter from 1 Oct 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2020: $795K; public on 10 Mar 2022
Quarter ended 31 Mar 2021: $2.0M; public on 13 May 2022
Quarter ended 31 Dec 2021: $2.9M, +259% on a year earlier; public on 10 Mar 2022
Quarter ended 31 Mar 2022: $3.0M, +49% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $4.1M, +42% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $3.4M, +39% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $3.1M, +8.4% on a year earlier; public on 9 Mar 2023
Quarter ended 31 Mar 2023: $6.8M, +125% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $3.1M, -22% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $3.9M, +16% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $7.2M, +133% on a year earlier; public on 7 Mar 2024
Quarter ended 31 Mar 2024: $566K, -92% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $536K, -83% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $1.0M, -73% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $665K, -91% on a year earlier; public on 6 Mar 2025
Quarter ended 31 Mar 2025: $2.2M, +284% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $3.1M, +474% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $2.5M, +139% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $2.6M, +286% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $982K, -55% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $1.1M, -66% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $586K, -77% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $1.4M; public on 10 Mar 2022
Quarter ended 31 Mar 2021: $3.0M; public on 13 May 2022
Quarter ended 31 Dec 2021: $2.2M, +60% on a year earlier; public on 10 Mar 2022
Quarter ended 31 Mar 2022: $531K, -82% on a year earlier; public on 13 May 2022
Quarter ended 30 Jun 2022: $1.9M, -52% on a year earlier; public on 11 Aug 2022
Quarter ended 30 Sep 2022: $424K, -50% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $1.4M, -38% on a year earlier; public on 9 Mar 2023
Quarter ended 31 Mar 2023: $838K, +58% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $420K, -78% on a year earlier; public on 11 Aug 2023
Quarter ended 30 Sep 2023: $1.4M, +235% on a year earlier; public on 10 Nov 2023
Quarter ended 31 Dec 2023: $469K, -66% on a year earlier; public on 7 Mar 2024
Quarter ended 31 Mar 2024: $705K, -16% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $862K, +105% on a year earlier; public on 13 Aug 2024
Quarter ended 30 Sep 2024: $1.4M, -3.5% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $888K, +89% on a year earlier; public on 6 Mar 2025
Quarter ended 31 Mar 2025: $1.5M, +117% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.3M, +48% on a year earlier; public on 13 Aug 2025
Quarter ended 30 Sep 2025: $1.4M, +4.0% on a year earlier; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $171K, -81% on a year earlier; public on 5 Mar 2026
Quarter ended 31 Mar 2026: $70K, -95% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $493K, -61% on a year earlier; public on 13 Aug 2026
Quarter ended 30 Sep 2026: $41K, -97% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 26; public on 14 Feb 2022
31 Mar 2022 report: 23; public on 16 May 2022
30 Jun 2022 report: 21; public on 15 Aug 2022
30 Sep 2022 report: 24; public on 14 Nov 2022
31 Dec 2022 report: 27; public on 14 Feb 2023
31 Mar 2023 report: 27; public on 15 May 2023
30 Jun 2023 report: 26; public on 14 Aug 2023
30 Sep 2023 report: 31; public on 14 Nov 2023
31 Dec 2023 report: 51; public on 14 Feb 2024
31 Mar 2024 report: 65; public on 15 May 2024
30 Jun 2024 report: 79; public on 14 Aug 2024
30 Sep 2024 report: 87; public on 14 Nov 2024
31 Dec 2024 report: 89; public on 14 Feb 2025
31 Mar 2025 report: 90; public on 15 May 2025
30 Jun 2025 report: 77; public on 14 Aug 2025
30 Sep 2025 report: 73; public on 14 Nov 2025
31 Dec 2025 report: 59; public on 17 Feb 2026
31 Mar 2026 report: 59; public on 15 May 2026
30 Jun 2026 report: 59; public on 14 Aug 2026
30 Sep 2026 report: 52; public on 16 Nov 2026
Workers in WARN layoff notices
Month from 1 Sep 2026: 96 published

What is unusual now

  • Made public in the last 90 days: it filed a WARN layoff notice covering 96 workers within 30 days (Waltham, MA, MA).
  • WARN layoff notice: filed a WARN layoff notice covering 96 workers within 30 days (Waltham, MA, MA) Public on 3 Sep 2026.
  • Insider net buying (open market): Insiders bought a net $146K in the last 12 months (the 12 months before: $3.5M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 7 published in the last 12 months, -12% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 24 insider trades

No trades in the last 90 days; the latest was filed 23 Dec 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
23 Dec 2025Lynx1 Capital Management LP and 1 other10% ownerBuy161,801$0.90$146KForm 4
21 May 2025Lynx1 Capital Management LP and 1 other10% ownerBuy2,588,794$1.20$3.1MForm 4
16 Dec 2024Weston Nichols and 1 other10% ownerBuy131,800$2.93$386KForm 4
19 Nov 2024Weston Nichols and 1 other10% ownerBuy947$4.34$4KForm 4
24 Sep 2024Barbara KlenckeDirectorBuy5,000$5.29$26KForm 4
27 Aug 2024Barbara KlenckeDirectorBuy10,000$5.61$56KForm 4
27 Aug 2024Zoran ZdraveskiSee RemarksSellafter exercising options164,686$5.78$952KForm 4
21 Dec 2023Timothy J BarberichDirectorBuy29,147$4.89$143KForm 4

52 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 5 opened a position, 12 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Lynx1 Capital Management LP8.0M33.4%$2.5MNo change
BVF Inc5.6M23.2%$1.7MNo change
Boothbay Fund Management, LLC3.4M14.2%$1.1M+2.6M+340%
Baker Bros. Advisors LP2.8M11.6%$876KNo change
Vanguard Capital Management LLC2.5M10.5%$790K+350K+16%
Acadian Asset Management LLC1.7M7.06%+387K+30%
Two Sigma Investments, LP1.6M6.86%$517K-305K-16%
Deer Management Co. LLC1.2M5.19%$386KNo change
Renaissance Technologies LLC1.2M5.04%$380K-119K-8.9%
DC Funds, LP630K2.63%$198KNo change

Company events

All 39 company events

In 12 months: 6 director or officer changes, 1 agreement ended, 1 restructuring, 1 delisting notice. Results releases and routine reports are left out.

FiledWhat happenedSource
16 Oct 2026Director or officer change8-K
30 Sep 2026Director or officer change8-K
11 Sep 2026Director or officer change8-K
2 Sep 2026Director or officer change; Restructuring costs announced; Delisting notice or listing transfer8-K
18 Aug 2026A major agreement ended8-K
2 Apr 2026Director or officer change8-K
26 Nov 2025Director or officer change8-K
3 Nov 2025Restructuring costs announced8-K

Layoff notices

All 1 layoff notices

1 notice in 12 months covering 96 workers. State WARN notices.

NoticeSiteWorkersJobs endSource
2 Sep 2026TScan Therapeutics Inc. (dba TScan)Waltham, MA, MA962 Nov 2026Notice

The 5 newest of 62 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

20 Aug 2024confirmed

Confirmed across sources Institutional holdings and Short interest and volume

TScan Therapeutics (TCRX): saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year, while it had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year. Two unrelated kinds of activity within 168 days.

  • Short interest and volume: Short interest spike, became public on 25 Jul 2024
  • Short interest and volume: Short interest spike, became public on 10 Aug 2024
  • Institutional holdings: Many funds opening a new position, became public on 14 Aug 2024
  • Short interest and volume: Short interest spike, became public on 27 Aug 2024
  • Short interest and volume: Short interest spike, became public on 12 Sep 2024
  • Short interest and volume: Short interest spike, became public on 25 Sep 2024
  • Short interest and volume: Short interest spike, became public on 10 Oct 2024
  • Short interest and volume: Short interest spike, became public on 25 Oct 2024
  • Short interest and volume: Short interest spike, became public on 13 Nov 2024
  • Short interest and volume: Short interest spike, became public on 27 Nov 2024
  • Short interest and volume: Short interest spike, became public on 11 Dec 2024
  • Short interest and volume: Short interest spike, became public on 25 Dec 2024
  • Short interest and volume: Short interest spike, became public on 14 Jan 2025
2022-06-30: 32022-09-30: 32022-12-31: 52023-03-31: 32023-06-30: 52023-09-30: 62023-12-31: 192024-03-31: 172024-06-30: 29
The quarter ended 30 Jun 2024 against the 8 quarters before it. this quarterearliernormal: 5
See the evidence (13 changes)

Short interest and volume: Short interest spike became public on 25 Jul 2024

TScan Therapeutics had 1.0M shares sold short in the 15 Jul 2024 report, 2.8× the same report last year.

This period
1.0M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
375K
Typical spread (median absolute deviation)
83K
How far from its usual level
+5.3
Same report last year
358K
History used
2,390 days
2023-07-14: 358K2023-07-31: 391K2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M
the 15 Jul 2024 report24 earlier reportsnormal: 375K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Aug 2024

TScan Therapeutics had 1.2M shares sold short in the 31 Jul 2024 report, 3.0× the same report last year.

This period
1.2M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
97K
How far from its usual level
+5.5
Same report last year
391K
History used
2,406 days
2023-07-31: 391K2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M
the 31 Jul 2024 report24 earlier reportsnormal: 379K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

TScan Therapeutics saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year.

This period
29 (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.0
Same quarter last year
5
History used
1,004 days
2022-06-30: 32022-09-30: 32022-12-31: 52023-03-31: 32023-06-30: 52023-09-30: 62023-12-31: 192024-03-31: 172024-06-30: 29
the quarter ended 30 Jun 20248 earlier quartersnormal: 5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 27 Aug 2024

TScan Therapeutics had 1.3M shares sold short in the 15 Aug 2024 report, 3.6× the same report last year.

This period
1.3M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
379K
Typical spread (median absolute deviation)
111K
How far from its usual level
+5.3
Same report last year
352K
History used
2,421 days
2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M
the 15 Aug 2024 report24 earlier reportsnormal: 379K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Sep 2024

TScan Therapeutics had 1.4M shares sold short in the 30 Aug 2024 report, 4.1× the same report last year.

This period
1.4M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
390K
Typical spread (median absolute deviation)
126K
How far from its usual level
+5.2
Same report last year
335K
History used
2,436 days
2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M
the 30 Aug 2024 report24 earlier reportsnormal: 390K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Sep 2024

TScan Therapeutics had 1.8M shares sold short in the 13 Sep 2024 report, 4.8× the same report last year.

This period
1.8M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
407K
Typical spread (median absolute deviation)
133K
How far from its usual level
+7.1
Same report last year
377K
History used
2,450 days
2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M
the 13 Sep 2024 report24 earlier reportsnormal: 407K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Oct 2024

TScan Therapeutics had 2.1M shares sold short in the 30 Sep 2024 report, 3.6× the same report last year.

This period
2.1M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
153K
How far from its usual level
+7.3
Same report last year
567K
History used
2,467 days
2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M
the 30 Sep 2024 report24 earlier reportsnormal: 418K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Oct 2024

TScan Therapeutics had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year.

This period
2.2M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
161K
How far from its usual level
+7.6
Same report last year
526K
History used
2,482 days
2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M
the 15 Oct 2024 report24 earlier reportsnormal: 418K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 13 Nov 2024

TScan Therapeutics had 2.2M shares sold short in the 31 Oct 2024 report, 4.6× the same report last year.

This period
2.2M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
170K
How far from its usual level
+6.9
Same report last year
471K
History used
2,498 days
2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M
the 31 Oct 2024 report24 earlier reportsnormal: 418K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Nov 2024

TScan Therapeutics had 2.3M shares sold short in the 15 Nov 2024 report, 5.5× the same report last year.

This period
2.3M (the 15 Nov 2024 report)
Normal report (median of 24 earlier)
418K
Typical spread (median absolute deviation)
182K
How far from its usual level
+6.9
Same report last year
416K
History used
2,513 days
2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M
the 15 Nov 2024 report24 earlier reportsnormal: 418K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Dec 2024

TScan Therapeutics had 2.3M shares sold short in the 29 Nov 2024 report, 6.2× the same report last year.

This period
2.3M (the 29 Nov 2024 report)
Normal report (median of 24 earlier)
451K
Typical spread (median absolute deviation)
220K
How far from its usual level
+5.7
Same report last year
373K
History used
2,527 days
2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M
the 29 Nov 2024 report24 earlier reportsnormal: 451K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Dec 2024

TScan Therapeutics had 2.3M shares sold short in the 13 Dec 2024 report, 6.6× the same report last year.

This period
2.3M (the 13 Dec 2024 report)
Normal report (median of 24 earlier)
498K
Typical spread (median absolute deviation)
294K
How far from its usual level
+4.2
Same report last year
355K
History used
2,541 days
2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M2024-12-13: 2.3M
the 13 Dec 2024 report24 earlier reportsnormal: 498K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 14 Jan 2025

TScan Therapeutics had 2.5M shares sold short in the 31 Dec 2024 report, 8.3× the same report last year.

This period
2.5M (the 31 Dec 2024 report)
Normal report (median of 24 earlier)
560K
Typical spread (median absolute deviation)
372K
How far from its usual level
+3.5
Same report last year
305K
History used
2,559 days
2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M2024-12-13: 2.3M2024-12-31: 2.5M
the 31 Dec 2024 report24 earlier reportsnormal: 560K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Oct 2026Filings record

    Director or officer change

  2. 30 Sep 2026Filings record

    Director or officer change

  3. 11 Sep 2026Filings record

    Director or officer change

  4. 3 Sep 2026Layoff notices change

    filed a WARN layoff notice covering 96 workers within 30 days (Waltham, MA, MA).

    See the evidence (1 source record)
    Notices in the window
    1
    Workers named
    96
    Window
    4 Aug 2026 to 3 Sep 2026

    Fires on a WARN notice after 30 days without one; notices within 30 days are summed.

  5. 3 Sep 2026Layoff notices record

    WARN notice: TScan Therapeutics Inc. (dba TScan), 96 workers, Waltham, MA, MA (dated 2 Sep 2026)

  6. 2 Sep 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  7. 2 Sep 2026Filings record

    Director or officer change

  8. 2 Sep 2026Filings record

    Delisting notice or listing transfer

  9. 2 Sep 2026Filings record

    Restructuring costs announced

  10. 18 Aug 2026Filings record

    A major agreement ended

  11. 2 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  12. 2 Apr 2026Filings record

    Director or officer change

  13. 24 Dec 2025Insiders record

    Lynx1 Capital Management LP (ten percent owner) and 1 other(s) bought 161,801 shares of TCRX ($145,621) (dated 23 Dec 2025)

  14. 26 Nov 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 26 Nov 2025Filings record

    Director or officer change

  16. 3 Nov 2025Filings record

    Restructuring costs announced

  17. 20 Aug 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 20 Aug 2025Filings record

    Director or officer change

  19. 22 May 2025Insiders record

    Lynx1 Capital Management LP (ten percent owner) and 1 other(s) bought 2,588,794 shares of TCRX ($3.1M) (dated 21 May 2025)

  20. 14 Jan 2025Short interest and volume change

    had 2.5M shares sold short in the 31 Dec 2024 report, 8.3× the same report last year.

    Same report last year: 305K; its normal report is 560K.

    See the evidence
    This period
    2.5M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    560K
    Typical spread (median absolute deviation)
    372K
    How far from its usual level
    +3.5
    Same report last year
    305K
    History used
    2,559 days
    2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M2024-12-13: 2.3M2024-12-31: 2.5M
    the 31 Dec 2024 report24 earlier reportsnormal: 560K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 25 Dec 2024Short interest and volume change

    had 2.3M shares sold short in the 13 Dec 2024 report, 6.6× the same report last year.

    Same report last year: 355K; its normal report is 498K.

    See the evidence
    This period
    2.3M (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    498K
    Typical spread (median absolute deviation)
    294K
    How far from its usual level
    +4.2
    Same report last year
    355K
    History used
    2,541 days
    2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M2024-12-13: 2.3M
    the 13 Dec 2024 report24 earlier reportsnormal: 498K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 23 Dec 2024Filings record

    A major agreement ended

  23. 17 Dec 2024Insiders record

    Nichols Weston (ten percent owner) and 1 other(s) bought 131,800 shares of TCRX ($385,718) (dated 16 Dec 2024)

  24. 11 Dec 2024Short interest and volume change

    had 2.3M shares sold short in the 29 Nov 2024 report, 6.2× the same report last year.

    Same report last year: 373K; its normal report is 451K.

    See the evidence
    This period
    2.3M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    451K
    Typical spread (median absolute deviation)
    220K
    How far from its usual level
    +5.7
    Same report last year
    373K
    History used
    2,527 days
    2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M
    the 29 Nov 2024 report24 earlier reportsnormal: 451K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 27 Nov 2024Short interest and volume change

    had 2.3M shares sold short in the 15 Nov 2024 report, 5.5× the same report last year.

    Same report last year: 416K; its normal report is 418K.

    See the evidence
    This period
    2.3M (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    418K
    Typical spread (median absolute deviation)
    182K
    How far from its usual level
    +6.9
    Same report last year
    416K
    History used
    2,513 days
    2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M
    the 15 Nov 2024 report24 earlier reportsnormal: 418K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 20 Nov 2024Insiders record

    Nichols Weston (ten percent owner) and 1 other(s) bought 947 shares of TCRX ($4,110) (dated 19 Nov 2024)

  27. 13 Nov 2024Short interest and volume change

    had 2.2M shares sold short in the 31 Oct 2024 report, 4.6× the same report last year.

    Same report last year: 471K; its normal report is 418K.

    See the evidence
    This period
    2.2M (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    418K
    Typical spread (median absolute deviation)
    170K
    How far from its usual level
    +6.9
    Same report last year
    471K
    History used
    2,498 days
    2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M
    the 31 Oct 2024 report24 earlier reportsnormal: 418K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 25 Oct 2024Short interest and volume change

    had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year.

    Same report last year: 526K; its normal report is 418K.

    See the evidence
    This period
    2.2M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    418K
    Typical spread (median absolute deviation)
    161K
    How far from its usual level
    +7.6
    Same report last year
    526K
    History used
    2,482 days
    2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M
    the 15 Oct 2024 report24 earlier reportsnormal: 418K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 10 Oct 2024Short interest and volume change

    had 2.1M shares sold short in the 30 Sep 2024 report, 3.6× the same report last year.

    Same report last year: 567K; its normal report is 418K.

    See the evidence
    This period
    2.1M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    418K
    Typical spread (median absolute deviation)
    153K
    How far from its usual level
    +7.3
    Same report last year
    567K
    History used
    2,467 days
    2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M
    the 30 Sep 2024 report24 earlier reportsnormal: 418K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 25 Sep 2024Short interest and volume change

    had 1.8M shares sold short in the 13 Sep 2024 report, 4.8× the same report last year.

    Same report last year: 377K; its normal report is 407K.

    See the evidence
    This period
    1.8M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    407K
    Typical spread (median absolute deviation)
    133K
    How far from its usual level
    +7.1
    Same report last year
    377K
    History used
    2,450 days
    2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M
    the 13 Sep 2024 report24 earlier reportsnormal: 407K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 25 Sep 2024Insiders record

    Klencke Barbara (director) bought 5,000 shares of TCRX ($26,450) (dated 24 Sep 2024)

  32. 12 Sep 2024Short interest and volume change

    had 1.4M shares sold short in the 30 Aug 2024 report, 4.1× the same report last year.

    Same report last year: 335K; its normal report is 390K.

    See the evidence
    This period
    1.4M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    390K
    Typical spread (median absolute deviation)
    126K
    How far from its usual level
    +5.2
    Same report last year
    335K
    History used
    2,436 days
    2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M
    the 30 Aug 2024 report24 earlier reportsnormal: 390K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 28 Aug 2024Insiders record

    Klencke Barbara (director) bought 10,000 shares of TCRX ($56,100) (dated 27 Aug 2024)

  34. 27 Aug 2024Short interest and volume change

    had 1.3M shares sold short in the 15 Aug 2024 report, 3.6× the same report last year.

    Same report last year: 352K; its normal report is 379K.

    See the evidence
    This period
    1.3M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    379K
    Typical spread (median absolute deviation)
    111K
    How far from its usual level
    +5.3
    Same report last year
    352K
    History used
    2,421 days
    2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M
    the 15 Aug 2024 report24 earlier reportsnormal: 379K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  35. 20 Aug 2024several at once

    saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year, while it had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year. Two unrelated kinds of activity within 168 days.

    See the evidence (13 changes)

    Short interest and volume: Short interest spike became public on 25 Jul 2024

    TScan Therapeutics had 1.0M shares sold short in the 15 Jul 2024 report, 2.8× the same report last year.

    This period
    1.0M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    375K
    Typical spread (median absolute deviation)
    83K
    How far from its usual level
    +5.3
    Same report last year
    358K
    History used
    2,390 days
    2023-07-14: 358K2023-07-31: 391K2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M
    the 15 Jul 2024 report24 earlier reportsnormal: 375K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Aug 2024

    TScan Therapeutics had 1.2M shares sold short in the 31 Jul 2024 report, 3.0× the same report last year.

    This period
    1.2M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    379K
    Typical spread (median absolute deviation)
    97K
    How far from its usual level
    +5.5
    Same report last year
    391K
    History used
    2,406 days
    2023-07-31: 391K2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M
    the 31 Jul 2024 report24 earlier reportsnormal: 379K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 14 Aug 2024

    TScan Therapeutics saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year.

    This period
    29 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.0
    Same quarter last year
    5
    History used
    1,004 days
    2022-06-30: 32022-09-30: 32022-12-31: 52023-03-31: 32023-06-30: 52023-09-30: 62023-12-31: 192024-03-31: 172024-06-30: 29
    the quarter ended 30 Jun 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 27 Aug 2024

    TScan Therapeutics had 1.3M shares sold short in the 15 Aug 2024 report, 3.6× the same report last year.

    This period
    1.3M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    379K
    Typical spread (median absolute deviation)
    111K
    How far from its usual level
    +5.3
    Same report last year
    352K
    History used
    2,421 days
    2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M
    the 15 Aug 2024 report24 earlier reportsnormal: 379K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Sep 2024

    TScan Therapeutics had 1.4M shares sold short in the 30 Aug 2024 report, 4.1× the same report last year.

    This period
    1.4M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    390K
    Typical spread (median absolute deviation)
    126K
    How far from its usual level
    +5.2
    Same report last year
    335K
    History used
    2,436 days
    2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M
    the 30 Aug 2024 report24 earlier reportsnormal: 390K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Sep 2024

    TScan Therapeutics had 1.8M shares sold short in the 13 Sep 2024 report, 4.8× the same report last year.

    This period
    1.8M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    407K
    Typical spread (median absolute deviation)
    133K
    How far from its usual level
    +7.1
    Same report last year
    377K
    History used
    2,450 days
    2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M
    the 13 Sep 2024 report24 earlier reportsnormal: 407K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Oct 2024

    TScan Therapeutics had 2.1M shares sold short in the 30 Sep 2024 report, 3.6× the same report last year.

    This period
    2.1M (the 30 Sep 2024 report)
    Normal report (median of 24 earlier)
    418K
    Typical spread (median absolute deviation)
    153K
    How far from its usual level
    +7.3
    Same report last year
    567K
    History used
    2,467 days
    2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M
    the 30 Sep 2024 report24 earlier reportsnormal: 418K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Oct 2024

    TScan Therapeutics had 2.2M shares sold short in the 15 Oct 2024 report, 4.3× the same report last year.

    This period
    2.2M (the 15 Oct 2024 report)
    Normal report (median of 24 earlier)
    418K
    Typical spread (median absolute deviation)
    161K
    How far from its usual level
    +7.6
    Same report last year
    526K
    History used
    2,482 days
    2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M
    the 15 Oct 2024 report24 earlier reportsnormal: 418K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 13 Nov 2024

    TScan Therapeutics had 2.2M shares sold short in the 31 Oct 2024 report, 4.6× the same report last year.

    This period
    2.2M (the 31 Oct 2024 report)
    Normal report (median of 24 earlier)
    418K
    Typical spread (median absolute deviation)
    170K
    How far from its usual level
    +6.9
    Same report last year
    471K
    History used
    2,498 days
    2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M
    the 31 Oct 2024 report24 earlier reportsnormal: 418K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Nov 2024

    TScan Therapeutics had 2.3M shares sold short in the 15 Nov 2024 report, 5.5× the same report last year.

    This period
    2.3M (the 15 Nov 2024 report)
    Normal report (median of 24 earlier)
    418K
    Typical spread (median absolute deviation)
    182K
    How far from its usual level
    +6.9
    Same report last year
    416K
    History used
    2,513 days
    2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M
    the 15 Nov 2024 report24 earlier reportsnormal: 418K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Dec 2024

    TScan Therapeutics had 2.3M shares sold short in the 29 Nov 2024 report, 6.2× the same report last year.

    This period
    2.3M (the 29 Nov 2024 report)
    Normal report (median of 24 earlier)
    451K
    Typical spread (median absolute deviation)
    220K
    How far from its usual level
    +5.7
    Same report last year
    373K
    History used
    2,527 days
    2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M
    the 29 Nov 2024 report24 earlier reportsnormal: 451K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Dec 2024

    TScan Therapeutics had 2.3M shares sold short in the 13 Dec 2024 report, 6.6× the same report last year.

    This period
    2.3M (the 13 Dec 2024 report)
    Normal report (median of 24 earlier)
    498K
    Typical spread (median absolute deviation)
    294K
    How far from its usual level
    +4.2
    Same report last year
    355K
    History used
    2,541 days
    2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M2024-12-13: 2.3M
    the 13 Dec 2024 report24 earlier reportsnormal: 498K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 14 Jan 2025

    TScan Therapeutics had 2.5M shares sold short in the 31 Dec 2024 report, 8.3× the same report last year.

    This period
    2.5M (the 31 Dec 2024 report)
    Normal report (median of 24 earlier)
    560K
    Typical spread (median absolute deviation)
    372K
    How far from its usual level
    +3.5
    Same report last year
    305K
    History used
    2,559 days
    2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M2024-08-15: 1.3M2024-08-30: 1.4M2024-09-13: 1.8M2024-09-30: 2.1M2024-10-15: 2.2M2024-10-31: 2.2M2024-11-15: 2.3M2024-11-29: 2.3M2024-12-13: 2.3M2024-12-31: 2.5M
    the 31 Dec 2024 report24 earlier reportsnormal: 560K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  36. 14 Aug 2024Institutional holdings change

    saw 29 13F filers open a new position in the quarter ended 30 Jun 2024, 5.8× the same quarter last year.

    Same quarter last year: 5; its normal quarter is 5.

    See the evidence
    This period
    29 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.0
    Same quarter last year
    5
    History used
    1,004 days
    2022-06-30: 32022-09-30: 32022-12-31: 52023-03-31: 32023-06-30: 52023-09-30: 62023-12-31: 192024-03-31: 172024-06-30: 29
    the quarter ended 30 Jun 20248 earlier quartersnormal: 5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  37. 10 Aug 2024Short interest and volume change

    had 1.2M shares sold short in the 31 Jul 2024 report, 3.0× the same report last year.

    Same report last year: 391K; its normal report is 379K.

    See the evidence
    This period
    1.2M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    379K
    Typical spread (median absolute deviation)
    97K
    How far from its usual level
    +5.5
    Same report last year
    391K
    History used
    2,406 days
    2023-07-31: 391K2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M2024-07-31: 1.2M
    the 31 Jul 2024 report24 earlier reportsnormal: 379K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 25 Jul 2024Short interest and volume change

    had 1.0M shares sold short in the 15 Jul 2024 report, 2.8× the same report last year.

    Same report last year: 358K; its normal report is 375K.

    See the evidence
    This period
    1.0M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    375K
    Typical spread (median absolute deviation)
    83K
    How far from its usual level
    +5.3
    Same report last year
    358K
    History used
    2,390 days
    2023-07-14: 358K2023-07-31: 391K2023-08-15: 352K2023-08-31: 335K2023-09-15: 377K2023-09-29: 567K2023-10-13: 526K2023-10-31: 471K2023-11-15: 416K2023-11-30: 373K2023-12-15: 355K2023-12-29: 305K2024-01-12: 260K2024-01-31: 244K2024-02-15: 253K2024-02-29: 188K2024-03-15: 188K2024-03-28: 219K2024-04-15: 420K2024-04-30: 398K2024-05-15: 382K2024-05-31: 483K2024-06-14: 512K2024-06-28: 608K2024-07-15: 1.0M
    the 15 Jul 2024 report24 earlier reportsnormal: 375K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 14 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 14 Jun 2024Filings record

    Director or officer change

Showing the newest 40 of 79 entries; narrow the window or the kind of data to see older ones.

Not listed: 70 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001783328
Ticker
TCRX
Domain
tscan.com
Employer name
TScan Therapeutics, Inc. (1 unverified)
Hq location
MA|WALTHAM|02451 (1 unverified)
Name
EX-21, tcrx-ex21.htm, TScan Securities Corporation, TScan Therapeutics, Inc.
  • DOL H-1B labor condition applications and PERM certifications98 data points6 Apr 2020 to 17 Aug 2026
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)99 records26 Jul 2019 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)376 data points31 Dec 2019 to 30 Sep 2026
  • SEC Form 4 insider transactions24 records, 80 data points22 Jul 2021 to 23 Dec 2025
  • FINRA short interest (twice monthly)422 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2752 data points1 Aug 2018 to 20 Nov 2026
  • WARN layoff notices (state labor agencies)1 record, 3 data points31 Aug 2026 to 2 Sep 2026